Advanz Hits Back Over £100m+ Fines For UK Liothyronine Pricing
Firm ‘Utterly Disagrees’ With CMA And Vows To Appeal Decision
Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.
You may also be interested in...
Advanz Pharma has failed in its appeal against a £40.9m fine imposed by the UK’s Competition and Markets Authority for its historical pricing practices for liothyronine tablets.
After a court last year overturned CMA fines of almost £90m imposed on Pfizer and marketing partner Flynn Pharma over pricing for phenytoin sodium capsules, the UK competition regulator has issued a fresh statement of objections after reassessing the case in light of the ruling’s guidance on how unfair pricing should be evaluated.
Firms censured by the UK’s CMA competition regulator over illegal deals that drove up the price of hydrocortisone for around a decade have vowed to appeal against the decision and the imposition of fines totaling more than £260m.